newsfilter
← Latest News
GlobeNewswire·

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced